Join Growin Stock Community!

Mira pharmaceuticals, inc.MIRA.US Overview

US StockHealthcare
(No presentation for MIRA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MIRA AI Insights

MIRA Overall Performance

MIRA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MIRA Recent Performance

-2.36%

Mira pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MIRA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MIRA Key Information

MIRA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MIRA Profile

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Price of MIRA

MIRA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MIRA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.16
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.99
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.16
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.99
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MIRA's latest earnings report released?

    The most recent financial report for Mira pharmaceuticals, inc. (MIRA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MIRA's short-term business performance and financial health. For the latest updates on MIRA's earnings releases, visit this page regularly.

  • How much cash does MIRA have?

    At the end of the period, Mira pharmaceuticals, inc. (MIRA) held Total Cash and Cash Equivalents of 2.64M, accounting for 0.35 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MIRA's EPS continuing to grow?

    According to the past four quarterly reports, Mira pharmaceuticals, inc. (MIRA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.18. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MIRA?

    Mira pharmaceuticals, inc. (MIRA)'s Free Cash Flow (FCF) for the period is -1.1M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 40.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.